Patents by Inventor Brett A. Hopkins
Brett A. Hopkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12157727Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.Type: GrantFiled: June 8, 2020Date of Patent: December 3, 2024Assignee: Merck Sharp & Dohme LLCInventors: Yongxin Han, Yongqi Deng, Hua Zhou, Meredeth A. McGowan, Hongjun Zhang, Wensheng Yu, Brett A. Hopkins, Xavier Fradera, Nunzio Sciammetta
-
Publication number: 20240336608Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, A, and B are as defined herein. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.Type: ApplicationFiled: March 27, 2024Publication date: October 10, 2024Applicant: Merck Sharp & Dohme LLCInventors: David A. Candito, Anthony Donofrio, Ronald Dale Ferguson, II, George Madalin Giambasu, Anmol Gulati, Andrew M. Haidle, Brett A. Hopkins, William P. Kaplan, Ping Liu, Michaelyn C. Lux, Xiao Mei Zheng, Ryan D. Otte, Alexander Pasternak, Elsie C. Yu
-
Publication number: 20240287022Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof wherein A, E, U, X, Y, Z, R1, R2 and n are as defined herein. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases. Also provided herein are pharmaceutical compositions comprising the compounds of the invention, or their pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier and methods of treatment with the compounds of the invention.Type: ApplicationFiled: June 23, 2022Publication date: August 29, 2024Applicant: Merck Sharp & Dohme LLCInventors: BRANDON D. CASH, GEORGE MADALIN GIAMBASU, ANDREW M. HAIDLE, BRETT A. HOPKINS, MATTHEW A. LARSEN, CHARLES A. LESBURG, PING LIU, RYAN QUIROZ, SULAGNA SANYAL, CATHERINE M. WHITE, XIN YAN, XIAO MEI ZHENG
-
Patent number: 12065438Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.Type: GrantFiled: November 1, 2019Date of Patent: August 20, 2024Assignee: Merck Sharp & Dohme LLCInventors: Yongxin Han, David Jonathan Bennett, Indu Bharathan, Liangqin Guo, Brett A. Hopkins, Xianhai Huang, Derun Li, Min Lu, Alexander Pasternak, David L. Sloman, Hongjun Zhang, Hua Zhou
-
Publication number: 20240246937Abstract: The invention discloses a synthesizing method of benzimidazole derivant and intermediate, which is characterized by the following: proceeding arylation among aryl halide and primary amine; adopting L-pro as additive, cuprous iodide as catalyst; proceeding molecular arylation coupling reaction for aryl iodide or aryl bromide and primary amine; adopting iodo phenylamine compound and bromophenylamine compound as starting material; synthesizing the material through several-step transformation.Type: ApplicationFiled: April 28, 2022Publication date: July 25, 2024Applicants: MERCK SHARP & DOHME LLC, MSD R&D (CHINA) CO., LTD.Inventors: George Madalin GIAMBASU, Andrew M. HAIDLE, Brett A. HOPKINS, James P. JEWELL, Matthew A. LARSEN, Charles A. LESBURG, Ping LIU, Qinglin PU, Sulagna SANYAL, Phieng SILIPHAIVANH, Matthew TUDOR, Catherine M. WHITE, Xin YAN, Lianyun ZHAO, Xiao Mei ZHENG, William P. KAPLAN, Michaelyn Claire LUX, Derun LI, Rebecca JOHNSON
-
Publication number: 20230183214Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.Type: ApplicationFiled: May 4, 2021Publication date: June 15, 2023Applicant: Merck Sharp & Dohme LLCInventors: Brandon D. CASH, Wenlang FU, George Madalin GIAMBASU, Andrew M. HAIDLE, Brett A. HOPKINS, Matthew A. LARSEN, Charles A. LESBURG, Ping LIU, Meredeth A. MCGOWAN, Qinglin PU, Sulagna SANYAL, Phieng SILIPHAIVANH, Catherine M. WHITE, Xin YAN
-
Publication number: 20220235028Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.Type: ApplicationFiled: June 8, 2020Publication date: July 28, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Yongxin Han, Yongqi Deng, Hua Zhou, Meredeth A. McGowan, Hongjun Zhang, Wensheng Yu, Brett A. Hopkins, Xavier Fradera, Nunzio Sciammetta
-
Publication number: 20210403469Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.Type: ApplicationFiled: November 1, 2019Publication date: December 30, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Yongxin Han, David Jonathan Bennett, Indu Bharathan, Liangqin Guo, Brett A. Hopkins, Xianhai Huang, Derun Li, Min Lu, Alexander Pasternak, David L. Sloman, Hongjun Zhang, Hua Zhou
-
Patent number: 10995085Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.Type: GrantFiled: March 16, 2020Date of Patent: May 4, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Yongxin Han, Abdelghani Achab, Yongqi Deng, Xavier Fradera, Craig Gibeau, Brett A. Hopkins, Derun Li, Kun Liu, Meredeth A. McGowan, Nunzio Sciammetta, David Sloman, Catherine White, Hongjun Zhang, Hua Zhou
-
Publication number: 20200216425Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.Type: ApplicationFiled: March 16, 2020Publication date: July 9, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Yongxin Han, Abdelghani Achab, Yongqi Deng, Xavier Fradera, Craig Gibeau, Brett A. Hopkins, Derun Li, Kun Liu, Meredeth A. McGowan, Nunzio Sciammetta, David Sloman, Catherine White, Hongjun Zhang, Hua Zhou
-
Patent number: 10647705Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.Type: GrantFiled: November 12, 2018Date of Patent: May 12, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Yongxin Han, Abdelghani Achab, Yongqi Deng, Xavier Fradera, Craig Gibeau, Brett A. Hopkins, Derun Li, Kun Liu, Meredeth A. McGowan, Nunzio Sciammetta, David Sloman, Catherine White, Hongjun Zhang, Hua Zhou
-
Publication number: 20190144433Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.Type: ApplicationFiled: November 12, 2018Publication date: May 16, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Yongxin Han, Abdelghani Achab, Yongqi Deng, Xavier Fradera, Craig Gibeau, Brett A. Hopkins, Derun Li, Kun Liu, Meredeth A. McGowan, Nunzio Sciammetta, David Sloman, Catherine White, Hongjun Zhang, Hua Zhou
